Showing 1 - 6 results of 6 for search 'Débora de Melo Gagliato', query time: 0.06s Refine Results
  1. 1
    Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

    Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds by Denis L. Jardim, Débora De Melo Gagliato, Mina Nikanjam, Donald A. Barkauskas, Razelle Kurzrock

    Published 2020-01-01
    Get full text
    Article
  2. 2
    Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology

    Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology by Denis L. Jardim MD, PhD, Débora de Melo Gagliato MD, Razelle Kurzrock MD

    Published 2018-12-01
    Get full text
    Article
  3. 3
    CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

    CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge by Debora de Melo Gagliato, Antonio C Buzaid, Jose Manuel Perez-Garcia, Antonio Llombart, Javier Cortes

    Published 2020-09-01
    Get full text
    Article
  4. 4
    The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.

    The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. by Young Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, Benedito Carneiro, Nisha Mohindra, Francis Joseph Giles, Praveen Ramakrishnan-Geethakumari, Joohyuk Sohn, Shuying Liu, Huiqin Chen, Naoto Ueno, Gabriel Hortobagyi, Ana Maria Gonzalez-Angulo

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

    Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective by Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Sergio D. Simon, Gilberto Amorim, Tomás Reinert, Luciana Landeiro, Débora de Melo Gagliato, Pedro Exman, Daniel Argolo, Gisah Guilgen, Max Mano, Laura Testa, Pedro Liedke, Romualdo Barroso, Mariana Sasse, Anna Maria Buehler

    Published 2022-05-01
    Get full text
    Article
  6. 6
    Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

    Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study by Leandro Jonata Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Daniele Xavier Assad, Daniel Fontes Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Kaliks, Maira Caleffi, Debora de Melo Gagliato, Marina Sahade, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Larissa Matos Almeida Moura, Julio Antonio Pereira de Araújo, Artur Katz, Max Senna Mano

    Published 2022-12-01
    Get full text
    Article

Search Tools: